Title: | An immunogenetic basis for lung cancer risk |
Journal: | Science |
Published: | 23 Feb 2024 |
Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38386728/ |
DOI: | https://doi.org/10.1126/science.adi3808 |
Citations: | 2 (2 in last 2 years) as of 8 Aug 2024 |
Title: | An immunogenetic basis for lung cancer risk |
Journal: | Science |
Published: | 23 Feb 2024 |
Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38386728/ |
DOI: | https://doi.org/10.1126/science.adi3808 |
Citations: | 2 (2 in last 2 years) as of 8 Aug 2024 |
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Cancer risk is influenced by inherited mutations, DNA replication errors, and environmental factors. However, the influence of genetic variation in immunosurveillance on cancer risk is not well understood. Leveraging population-level data from the UK Biobank and FinnGen, we show that heterozygosity at the human leukocyte antigen (HLA)-II loci is associated with reduced lung cancer risk in smokers. Fine-mapping implicated amino acid heterozygosity in the HLA-II peptide binding groove in reduced lung cancer risk, and single-cell analyses showed that smoking drives enrichment of proinflammatory lung macrophages and HLA-II+ epithelial cells. In lung cancer, widespread loss of HLA-II heterozygosity (LOH) favored loss of alleles with larger neopeptide repertoires. Thus, our findings nominate genetic variation in immunosurveillance as a critical risk factor for lung cancer.</p>
Application ID | Title |
---|---|
61123 | Dissecting immune determinants of cancer predisposition and development |
Enabling scientific discoveries that improve human health